Povidone-Iodine/Dexamethasone appeared to be safe and effective in patients with acute adenoviral conjunctivitis, according to a study published in American Journal of Opthalmology.
Around 79% of patients got relief from Adeno conjunctivitis when treated with PVP-I/dexamethasone as compared to 62% when treated with PVP-I. Viral conjunctivitis is a highly contagious acute conjunctival infection usually caused by adenovirus. Symptoms include irritation, photophobia, and watery discharge.
Jay S Pepose and his associates conducted a study to evaluate the efficacy and safety of an ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1% in patients with acute adenoviral conjunctivitis.
The trial conducted was multicentered, randomized, vehicle-controlled, double-masked which involved 144 patients with a positive Rapid Pathogen Screening Adeno-Detector Plus TM test. The patients were randomly given PVP-I 0.6%/dexamethasone 0.1%, PVP-I 0.6%, or vehicle in equal proportion 1:1:1 bilaterally 4 times daily for 5 days. Patients were evaluated on days 3, 6, and 12.
The study found that the proportion with adenoviral eradication was higher with PVP-I/dexamethasone than vehicle at the day 3 (35.4% vs 8.7% ) and day 6 (79.2% vs 56.5%) visits and versus PVP-I (day 3 visit, 32.0%; day 6 visit, 62.0%).
Treatment-emergent adverse events (AEs) occurred in 69.0% (vehicle), 62.7% (PVP-I), and 53.4% (PVP-I/dexamethasone) of patients.
The study concluded that PVP-I/dexamethasone appeared safe and well tolerated, and significantly improved clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis.
For more information log on to
Latest posts by Vinay Singh (see all)
- Inguinal Hernia in men associated with increase in estrogen - October 17, 2018
- Eravacycline approved for complicated Intra-Abdominal Infections - October 17, 2018
- New Intravitreal implant approved for posterior segment Uveitis - October 17, 2018